View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 1, 2019

Medtronic introduces Valiant Navion graft system in Japan

Medtronic has launched the Valiant Navion thoracic stent graft system in Japan, following approval from the country’s Ministry of Health, Labour and Welfare (MHLW).

Medtronic has launched the Valiant Navion thoracic stent graft system in Japan, following approval from the country’s Ministry of Health, Labour and Welfare (MHLW).

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The graft system is for use for the repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD).

Previously, the device secured the US Food and Drug Administration (FDA) approval and the European CE-Mark.

Valiant Navion is based on the Valiant Captivia thoracic stent graft system and is designed to expand patient applicability.

Both the proximal covered CoveredSeal and proximal bare metal FreeFlo stent configurations are said to feature tip capture accuracy.

Medtronic aortic business vice-president and general manager John Farquhar said: “In just one year, the Valiant Navion system has achieved significant impact in expanding minimally invasive treatment options to patients globally.

“By designing a device with a global patient population in mind, we have ultimately broadened patient applicability and allowed for more patients to receive endovascular repair.”

Separately, the company launched the Patient Programmer technology for deep brain stimulation (DBS) therapy in the US.

The programmer uses a custom-configured Samsung mobile device to enable therapy management for more than 150,000 patients who received the company’s DBS implants.

It integrates Samsung Knox security technology to protect both the device and the patient.

The Patient Programmer consists of a programmer handset and a communicator, which links the implant to the programmer handset.

Patients can use the programmer to make changes to their therapy settings, turn the therapy on / off and check the neurostimulator’s battery by holding the communicator over the implanted device.

Furthermore, clinicians can coordinate with patients to modify DBS therapy settings between clinic visits.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network